Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. (NASDAQ: MDXG) is a regenerative medicine and advanced wound care company whose activities generate frequent news across clinical, regulatory, financial, and legal fronts. The company develops and markets placental tissue–based allografts and other biomaterial products used in chronic and hard-to-heal wounds, burn care, and selected surgical applications, and it regularly updates investors and clinicians on developments affecting these businesses.
News about MiMedx often includes announcements of new product launches and portfolio expansions, such as the introduction of EPIXPRESS, a lyophilized human placental-based allograft, and the exclusive U.S. distribution agreement for RegenKit Wound Gel. The company also highlights clinical and scientific milestones, including peer-reviewed publications on Purion processed human amniotic membrane allografts and interim results from randomized controlled trials like the CAMPAIGN study evaluating EPIEFFECT in nonhealing diabetic foot ulcers.
Investors following MDXG can expect regular earnings releases, conference call details, and commentary on reimbursement policy changes, particularly regarding Medicare rules for skin substitutes and advanced wound care products. MiMedx uses press releases to discuss how reimbursement reforms may affect its market and to describe its operational and commercial positioning.
In addition, MiMedx appears in news related to legal and regulatory matters, including litigation with former employees and references to FDA communications on specific products. Coverage may also include the company’s participation in investor conferences and clinical meetings such as the Symposium on Advanced Wound Care. For those tracking MDXG, this news stream provides insight into product performance, scientific evidence, regulatory context, and corporate strategy over time.
MIMEDX (Nasdaq: MDXG) reported Q1 2026 net sales of $59 million, down 33% year-over-year, driven by a 60% decline in Wound sales while Surgical sales rose 13%.
The company cut 2026 net sales guidance to $260–$290 million and now expects ~breakeven Adjusted EBITDA for 2026; cash was $160 million at March 31, 2026.
MiMedx (Nasdaq: MDXG) will report first quarter 2026 operating and financial results for the period ended March 31, 2026, after market close on Wednesday, April 29, 2026. The senior management team will host a webcast and conference call beginning at 4:30 p.m. Eastern Time that day.
According to the company, U.S. and international dial‑in numbers and a conference ID are provided, and a replay will be available on the company website for approximately 30 days following the event.
MiMedx (Nasdaq: MDXG) announced a restructuring to reduce annual operating expenses by approximately $40 million and expects a one-time $4 million restructuring charge in Q2 2026. The company eliminated the Chief Operating Officer role and plans additional commentary with Q1 2026 results in late April.
Management said Surgical will receive further investment while Wound Care is recovering slowly after the January 1 Medicare reimbursement reduction.
MiMedx Group (Nasdaq: MDXG) will sponsor and present at two leading wound care conferences: SAWC Spring 2026 (April 8–12, Charlotte) and DLS 2026 (April 8–11, Washington, D.C.).
Activities include sponsored symposia, multiple poster and oral clinical presentations, and exhibit booths to showcase peptide-based and placental allograft wound-care technologies.
MiMedx (Nasdaq: MDXG) announced the commercial launch of CHORIOFIX on March 23, 2026, a lyophilized placental allograft composed of two chorion layers with an intact intermediate layer.
The company said CHORIOFIX is its thickest product to date, designed to improve handling, positioning and suturing, and has been added to the prospective randomized CAMPAIGN trial to evaluate performance versus standard of care in non-healing diabetic foot ulcers.
MiMedx (Nasdaq: MDXG) launched AMNIOFIX Thyroid Shields, a DHACM allograft line for endocrine surgery designed to protect the recurrent laryngeal nerve and parathyroid glands after thyroidectomy.
The product is preconfigured for operating-room use, shelf-stable up to five years, manufactured with the PURION process, and supported by a retrospective single-center study showing a 76% reduction in 24-hour RLN damage (3.4% vs 14.4%, p<0.01).
MIMEDX (Nasdaq: MDXG) reported record 2025 results with Q4 net sales $118M (+27% YoY) and full-year net sales $419M (+20% YoY). Q4 GAAP net income was $15M and full-year net income was $49M. Adjusted EBITDA for Q4 was $29M (25% of net sales). Cash totaled $166M at year-end. The board authorized a $100M share repurchase over two years. For 2026 the company estimates net sales of $340–360M and adjusted EBITDA margin in the mid-to-high teens.
MiMedx (Nasdaq: MDXG) will report fourth quarter and full year 2025 operating and financial results after market close on Wednesday, February 25, 2026.
The senior management team will host a webcast and conference call beginning at 4:30 p.m. ET on February 25. A replay will be available on the company website for approximately 30 days.
MIMEDX (Nasdaq: MDXG) entered an exclusive distribution agreement with Summit Products Group on February 4, 2026 to add three 510(k) cleared surgical and wound-care products: Hydrelix, NovaForm, and G4Derm Plus.
The products include a soluble bovine collagen powder, a bioglass-collagen wound matrix, and a flowable peptide matrix designed to support wound healing and manage bioburden.
MIMEDX (Nasdaq: MDXG) is marking the 15th anniversary of its placental allografts EPIFIX and AMNIOFIX, used in wound care and surgical recovery. Together they appear in nearly 100 clinical and scientific publications, including seven randomized controlled trials, and are described as the industry’s most studied placental allografts.
The company highlighted broad clinical use across more than a dozen surgical specialties and credited employees for advancing its products and peer-reviewed evidence base.